Crushing and Splitting Direct-Acting Antivirals for Hepatitis C Virus Treatment: A Case Series and Literature Review

Kristen Whelchel,1,2 Autumn D. Zuckerman,1,2 David E. Koren,2,3 Caroline Derrick,3 Jeannette Bouchard,4,5,6 and Cody A. Chastain1,6

1Specialty Pharmacy Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA; 2Department of Pharmacy Services, Temple University Health System, Philadelphia, Pennsylvania, USA; 3Department of Infectious Disease, University of South Carolina, Columbia, South Carolina, USA; 4Department of Pharmacy, University of South Carolina, Columbia, South Carolina, USA; and 5Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Limited data exist regarding the use of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) in patients who are unable to swallow tablets. This case series describes HCV treatment in patients requiring tablet manipulation, providing evidence for safety and effectiveness of HCV DAA tablet manipulation.

Keywords. chronic; crushing; deglutition; direct-acting antiviral; hepatitis C; splitting; tablet.

KEY POINTS
This report comprises the largest and most comprehensive case series for hepatitis C virus (HCV) treatment with direct acting antiviral (DAA) tablet manipulation. The results suggest safety and effectiveness of HCV treatment requiring DAA tablet manipulation.

Chronic hepatitis C virus (HCV) affects >70 million people worldwide [1] and is an ongoing epidemic within the United States where approximately 2.4 million people are living with HCV [2]. Many benefits are observed among people treated for HCV who achieve a sustained virologic response (SVR), or virologic cure, such as reductions in liver-related morbidity and mortality, extrahepatic manifestations, and all-cause mortality [3–6]. The introduction of direct-acting antivirals (DAAs) has changed the HCV treatment landscape and offers safe and highly effective all-oral regimens over previous regimens with extended durations and numerous adverse drug effects. The evolution in HCV pharmacotherapy is recognized by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, which recommend treating almost all patients infected with HCV with oral DAAs and highlight SVR rates >90% for most patient populations [7]. Nonetheless, HCV treatment options for patients with difficulties swallowing whole tablets have largely remained unclear.

DAAs have been evaluated in many patient populations, yet limited data exist regarding use in patients unable to swallow whole tablets. Despite this paucity of data, clinical scenarios may require tablet manipulation (ie, crushing or splitting) due to dysphagia, physiological changes, concurrent medications, or disease states [8]. While it is often accepted that taking oral medications can be troublesome for children and adolescents due to medication taste and swallowing difficulties [9], adult populations also report a swallowing difficulty prevalence as high as 60% [8,10].

With the increasing use of DAAs, including among niche populations such as pediatric patients and HCV-positive organ transplant recipients, and the potential impact splitting or crushing may have on tablet integrity [11], there is an unmet need for outcomes data in cases that require DAA tablet manipulation. The aim of this case series is to describe the safety and effectiveness of HCV treatment requiring DAA tablet manipulation in real-world scenarios. Additional literature is reviewed here to present an inclusive resource to practitioners.

CASE SERIES
We conducted a retrospective case series of patients prescribed DAA therapy requiring tablet manipulation from January 2013 to December 2019 at 3 academic tertiary medical centers in the United States. This study was approved by the institutional review board (IRB) at Vanderbilt University Medical Center as an exempt study. Review was not required by the IRB of Temple University or the University of South Carolina. Baseline demographics, comorbidities, HCV characteristics, reasons for and methods of DAA administration, DAA treatment information, and outcomes were collected (Table 1). Among 10 patients identified, most were male (60%), treatment naive (70%), with HCV genotype 1a infection (60%) and had a median age of 61 years (interquartile range [IQR], 56–68 years). Half were Black, and half were White. DAAs included sofosbuvir/velpatasvir (50%), ledipasvir/sofosbuvir (30%), and glecaprevir/pibrentasvir (20%). Patients either crushed (70%) or split (30%) tablets. Reasons for tablet manipulation included inability to swallow tablets due to history of cancer (60%); difficulty swallowing large tablets (10%); short gut syndrome requiring...
| Age, y | Sex | GT | Fibrosis Stage | Baseline Viral Load, IU/mL | Previous HCV Treatment | Method of Administration | Pertinent Medical History | Management of Potential Drug Interactions With DAA | Patient-Reported Adherence | SVR_12 Achieved |
|-------|-----|----|----------------|--------------------------|-----------------------|------------------------|--------------------------|--------------------------------|-------------------------|-------------------|
| 67    | Male| 1a | FIB-4 1.35*    | >25 million              | Naive                 | Crushed and taken by PEG tube | NAT* heart/kidney transplant, HTN, HLD, DM, GI bleeding | Atorvastatin, changed to pravastatin; quetiapine, monitored; tacrolimus, monitored; omeprazole, dosed simultaneously with GLE/PIB | No missed doses | Yes |
| 68    | Female| 1a | FIB-4 1.71*   | 1 483 153                | Naive                 | Crushed and taken by PEG tube | NAT* heart/kidney transplant, TTR amyloidosis, ESRD | Pantoprazole, dosed simultaneously with GLE/PIB; oxycodone, monitored; tacrolimus, monitored | 2 missed doses | Yes |
| 71    | Male| 1a | F2–F3 (cirrhotic changes on imaging) | 447 762 | Naive | Split in half and taken by mouth | Short gut syndrome, ischemic colitis requiring colectomy | NA | No missed doses | Yes |
| 61    | Male| 1a | F0             | 2 257 722                | Experienced (IFN)     | Crushed and taken with a small amount of orange juice | h/o squamous cell carcinoma of larynx, HTN, DM, HLD | Magnesium, separated from LDV/SOF by 4 h | No missed doses | LT FU (undetectable at EOT) |
| 60    | Male| 1a | F0–F1          | >25 million              | Naive                 | Crushed and taken by mouth | h/o laryngeal cancer | NA | Several missed doses | LT FU (undetectable at EOT) |
| 60    | Male| 3  | F2–F3 (cirrhotic changes on imaging) | 68 671 | Naive | Crushed and taken by PEG tube | h/o carcinoma of tonsil, HCC, GERD, HTN | NA | 1 missed dose | Yes |
| 73    | Male| 3  | F2             | 8560                     | Naive                 | Crushed and taken by mouth | h/o malignant neoplasm of supraglottis | NA | No missed doses | Yes |
| 41    | Female| 3 | F0             | 26 8231                 | Naive                 | Split in half and taken on gelatin | Scoliosis with Harrington rod, BMI 17.8 kg/m² | NA | No missed doses | Yes |
| 60    | Female| 1a | F0             | 3 46315                 | Experienced (SMV + SOF) | Crushed and taken sprinkled on applesauce | h/o squamous cell carcinoma of larynx, GERD, HTN, CAD | NA | 31 missed doses | Yes |
| 50    | Female| 3 | F4             | 3 0 7 84                | Experienced (IFN)     | Split in quarters and taken by mouth | Decompensated cirrhosis, h/o submandibular malignant mass | Calcium carbonate, separated from SOF/VEL by 4 h; ranitidine, held while on SOF/VEL | 4 missed doses | LT FU (undetectable at EOT) |

Abbreviations: BMI, body mass index; CAD, coronary artery disease; DAA, direct-acting antiviral; DM, diabetes mellitus; EOT, end of treatment; ESRD, end-stage renal disease; FIB-4, Fibrosis-4 Index for Liver Fibrosis; GERD, gastroesophageal reflux disease; GI, gastrointestinal; GLE, glecaprevir; GT, genotype; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HLD, hyperlipidemia; h/o, history of; HTN, hypertension; IFN, interferon; LDV, ledipasvir; LTFU, lost to follow-up; NA, not applicable; NAT*, nucleic acid test positive; PEG, percutaneous endoscopic gastrostomy; PIB, pibrentasvir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR_12, sustained virologic response at 12 weeks; TTR, transthyretin; VEL, velpatasvir.

*FIB-4 is provided when other staging data not available.
enteral feeding (10%); and inpatient intubation after multiorgan transplant (20%). All patients were prescribed 12 weeks of DAA therapy and had undetectable HCV viral loads by day 56 on treatment. The median time to on-treatment viral load assessment was 33 days (IQR, 27–44 days). All patients with available data (n = 7) achieved SVR at 12 weeks (SVR_{12}). Three patients achieved undetectable viral loads at end of treatment but were lost to follow-up prior to SVR_{12} assessments. No patients experienced severe adverse events, but unpleasant taste was reported (n = 4). Eight patients (80%) completed treatment with ≤4 missed doses. One patient reported missing “several” doses; another completed treatment 31 days after the anticipated end of treatment date and still achieved SVR_{12}.

**DISCUSSION**

The need to manipulate HCV DAAs reflects a real-world clinical challenge in delivering HCV care. Although pellets of commonly prescribed HCV DAAs are now approved for pediatric use, these are unlikely to be used in the real-world adult population as multiple packets (ranging from 2 to 6) would be needed to constitute an adult dose, which may exceed the costs of standard tablets and prove a barrier during the insurance authorization process. Current DAA tablet formulations are not enteric-coated or sustained-release, so tablets can be split or crushed without concerns for degrading the drug release mechanism. However, stability and pharmacokinetic data of crushed or split tablets are not readily available. Reports of DAA tablet manipulation are limited to 2 small phase 1 pharmacokinetic studies [12, 13] and case reports (Table 2) [14–23]. Pijnenburg et al [12] conducted a phase 1, single-dose trial evaluating pharmacokinetic data of elbasvir/grazoprevir in 11 healthy adult volunteers. Pharmacokinetic similarities were demonstrated between crushed and suspended elbasvir/grazoprevir tablets compared with whole tablets; thus, crushed tablets can be an administration option for patients with swallowing disorders. Oberoi et al [13] evaluated pharmacokinetic data for a single dose of glecaprevir/pibrentasvir in 25 healthy adults. Among 5 different administration mode groups evaluated (ie, whole tablets, halved tablets, crushed tablets, tablets ground into a powder, and ground powder mixed in Jell-O), all manipulation strategies had clinically significant impact on drug exposure except halving tablets, which did not affect exposure levels. These data comprise the largest and most comprehensive case series of safety and efficacy data for HCV DAA tablet manipulation and fill important data gaps related to DAA tablet manipulation. This series describes the first cases of tablet manipulation in patients with genotype 3 infection and a patient with decompensated cirrhosis. The definition of tablet manipulation in this current series expands on previous treatment and achieved SVR_{12}.

To date, 11 individual case reports of DAA tablet manipulation have been published (Table 2) [14–24]. Five cases describe treatment with sofosbuvir/velpatasvir in patients with HCV genotypes 1a, 1b, 2b, and 4 [19–23]. In these cases, patients crushed tablets and either administered by mouth [19, 22, 23] or via percutaneous endoscopic gastrostomy (PEG) tube [20, 21]. SVR_{12} was achieved in 4 patients [19, 20, 22, 23] and was not reported in the remaining case [21]. The addition of the case series described here doubles the number of sofosbuvir/velpatasvir reported tablet manipulation cases and expands to previously unreported patient populations treated with sofosbuvir/velpatasvir. These newly reported patients include 4 with HCV genotype 3 infection, 1 patient with decompensated cirrhosis, and 2 patients who split tablets. Ledipasvir/sofosbuvir tablet manipulation was previously reported in 3 cases, all achieving SVR_{12} [16–18]. All patients had HCV genotype 1, and tablets were crushed, dissolved, and administered by PEG tube [16, 17] or gastrostomy button [18]. Three additional cases of treatment with ledipasvir/sofosbuvir in HCV genotype 1 patients with oral administration after crushing and splitting tablets are newly reported here. Additional published case reports include 2 patients with genotype 1a HCV treated with elbasvir/grazoprevir [14, 24] and a genotype 1b patient treated with glecaprevir/pibrentasvir [15]; all patients achieved SVR_{12} [14, 15, 24].

Recently Waldman et al described treatment of 25 patients with glecaprevir/pibrentasvir after receiving heart or heart/ kidney transplants from HCV nucleic acid test–positive (NAT”) donors, 8 of whom crushed GLE/PIB a median of 6 days during the course of HCV treatment [25]. There was no difference in SVR rates between the 2 groups. Our data add to this report and include 2 additional cases of crushed glecaprevir/pibrentasvir following organ transplant from HCV NAT” donors who received crushed tablets through the entire course of DAA treatment and achieved SVR_{12}.

These data comprise the largest and most comprehensive case series of safety and efficacy data for HCV DAA tablet manipulation and fill important data gaps related to DAA tablet manipulation. This series describes the first cases of tablet manipulation in patients with genotype 3 infection and a patient with decompensated cirrhosis. The definition of tablet manipulation in this current series expands on previous literature to include splitting in addition to crushing, thus reflecting a wider variety of real-world practice. These data additionally build on previous reports of HCV NAT” donor organ transplants with longer duration of tablet manipulation during treatment. The presence of patients lost to follow-up reflect the real-world challenges of HCV treatment despite high efficacy. As there were no severe adverse effects reported in this series or in any of the cases from the literature, these data suggest safety of DAA manipulation.

The safety and efficacy of HCV treatment despite DAA tablet manipulation seen in our case series align with existing literature to support use of tablet manipulation of HCV DAAs when needed; however, further study remains warranted to examine tablet stability and effects on pharmacokinetic and safety profiles. In summary, this real-world case series of 10 cases of HCV DAA manipulation and review of the published literature demonstrate the safety and efficacy of tablet manipulation and provide a resource for clinicians treating HCV amid challenging clinical circumstances.
| First Author          | Age, y | Sex | GT     | Fibrosis Stage | DAA            | Previous HCV Treatment | Method of Administration | Reason for Tablet Manipulation                        | SVR<sub>12</sub> Achieved | Adverse Events |
|-----------------------|--------|-----|--------|----------------|-------------------|------------------------|-------------------------|--------------------------------------------------------|-----------------------------|----------------|
| Yap [14]              | 63     | Male| 1a     | Noncirrhotic   | EBV/GRZ          | Naive                  | Crushed, dissolved, PEG | Dysphagia due to head and neck cancer                  | Yes                         | NR             |
| Shah [24]             | 64     | Female | 1a | Noncirrhotic | EBV/GRZ | Experienced (PEG-IFN/RBV) | Crushed, dissolved, PEG | Esophageal dysmotility disorder | Yes | None |
| Tanaka [15]           | 41     | Female | 1b | Noncirrhotic | GLE/PIB | Naive | Crushed, dissolved, PEG | Dysphagia with spina bifida and hydrocephalus | Yes | Constipation |
| Huffman [16]          | 57     | Female | 1b | Noncirrhotic | LDV/SOF | Naive | Crushed, dissolved, PEG | Odynophagia with h/o head and neck cancer | Yes | Fatigue |
| Jindracek [17]        | 61     | Male | 1 | Compensated cirrhosis | LDV/SOF | Experienced (PEG-IFN/RBV) | Crushed, dissolved, PEG | Dysphagia due to pharyngeal ulcer, h/o head and neck cancer | Yes | None |
| Fulco [18]            | 19     | Female | 1a | Noncirrhotic | LDV/SOF | Naive | Crushed, dissolved, gastrosomy button | Gastrosomy button for historical failure to thrive | Yes | NR |
| Lalanne [19]          | 70     | Female | 1b | Hepatocellular carcinoma, noncirrhotic | SOF/VEL | Naive | Crushed and taken with food and an acidic beverage | Dysphagia due to previous oropharyngectomy, h/o head and neck cancer | Yes | None |
| Van Seyen [20]        | 54     | Male | 2b | Normal liver enzymes | SOF/VEL | Not reported | Crushed, dissolved, PEG | Left-sided hemiparesis following stroke | Yes | None |
| Caceres-Velasco [21]  | 53     | NR | 1a | Advanced fibrosis and thrombo-cytopenia | SOF/VEL | Naive | Crushed, dissolved, PEG | h/o head and neck cancer with subtotal maxillectomy, PEG for nutritional feedings | NR | None |
| Puebla Villaescusa [22] | 65    | Male | 4 | Noncirrhotic | SOF/VEL | Not reported | Crushed, dissolved in water, and taken by mouth | Dysphagia with h/o head and neck cancer | Yes | Bitter taste |
| Mogul [23]            | 62     | Female | 4 | Noncirrhotic | SOF/VEL | Naive | Crushed and taken on soft food | Dysphagia | Yes | Headache and fatigue |

Abbreviations: DAA, direct-acting antiviral; EBV, elbasvir; GLE, glecaprevir; GRZ, grazoprevir; GT, genotype; HCV, hepatitis C virus; h/o, history of; LDV, ledipasvir; NR, not reported; PEG, percutaneous epigastric gastrosomy; PEG-IFN, pegylated interferon; PIB, pibrentasvir; RBV, ribavirin; SOF, sofosbuvir; SVR<sub>12</sub>, sustained virologic response at 12 weeks; VEL, velpatasvir.
Notes

Potential conflicts of interest. D. E. K. is an independent consultant for AbbVie and has participated on an advisory panel for Gilead Sciences. All other authors report no potential conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2:161–76.
2. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology 2019; 69:1020–31.
3. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584–93.
4. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158:329–37.
5. Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016; 63:408–17.
6. Carrat F, Fontaine H, Dorival C, et al; French ANRS CO22 Hepather Cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393:1453–64.
7. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 26 February 2021.
8. Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realize. Pharm Pract 2005; 15:411–14.
9. Hansen DL, Tulinius D, Hansen EH. Adolescents’ struggles with swallowing tablets: barriers, strategies and learning. Pharm World Sci 2008; 30:65–9.
10. Schiele JT, Quiruz R, Klimm HD, et al. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol 2013; 69:937–48.
11. Gill D, Spain M, Edlund BJ. Crushing or splitting medications: unrecognized hazards. J Gerontol Nurs 2012; 38:8–12.
12. Pijnenburg DWM, van Seyen M, Abbink EJ, et al. Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection. J Antimicrob Chemother 2020; 75:2661–5.
13. Oberoi RK, Zhao W, Sidhu DS, et al. A phase 1 study to evaluate the effect of crushing, cutting into half, or grinding of glecaprevir/pibrentasvir tablets on exposures in healthy subjects. J Pharm Sci 2018; 107:1724–30.
14. Yap JE, Jaiswal P, Ton L, et al. Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube. J Clin Pharm Ther 2018; 43:730–2.
15. Tanaka Y, Tateishi R, Koike K. Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature. Clin J Gastroenterol 2019; 12:588–91.
16. Huffman V, Andrade DC, Sherman E, et al. Treatment of chronic hepatitis C virus infection with crushed ledipasvir-sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection. Am J Health Syst Pharm 2021; 78:36–40.
17. Jindracek L, Stark J. Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered via a percutaneous endoscopic gastrostomy tube. J Pharm Pract 2018; 31:522–4.
18. Fulco PP, Sterling RK, Lavoie SR. Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus. Am J Health Syst Pharm 2017; 74:1761–2.
19. Lalanne S, Jézéquel C, Tron C, et al. Therapeutic drug monitoring-guided crushed sofosbuvir-velpatasvir treatment: a case study. Ther Drug Monit 2020; 42:163–4.
20. van Seyen M, Samson AD, Cullen L, et al. Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder. Int J Antimicrob Agents 2020; 55:105934.
21. Cáceres-Velasco C, Gómez-Sayago L, Marín-Ventura L, et al. Safe administration of sofosbuvir/velpatasvir in a patient with percutaneous endoscopic gastrostomy. Eur J Hosp Pharm 2020; 27(Suppl 1):A163–63.
22. Puebla Villaescusa A, Gozalo Esteve I, Larrea Vargas M, et al. Successful treatment of chronic hepatitis C infection with crushed sofosbuvir/velpatasvir. Eur J Hosp Pharm 2020; 27(Suppl 1):A164–64.
23. Mogul A, Texeira E, McAuliffe L, et al. Effectiveness of crushed sofosbuvir-velpatasvir in a patient with dysphagia. Am J Health Syst Pharm 2020; 77:417–8.
24. Shah RB, Garrett KL, Brotherton AL, Noska AJ. Elbasvir/grazoprevir administered for 12 weeks via percutaneous endoscopic gastrostomy tube achieves sustained virologic response: a case report and a review of the literature. Pharmacotherapy 2021; 41:634–40.
25. Waldman G, Bethea E, Gustafson J, et al. Use of crushed glecaprevir/pibrentasvir in hepatitis C positive donor heart transplant recipients. J Heart Lung Transplant 2020; 39(4 Suppl):S89–96.